Sign up for a free trial now
  • Login
  • Subscribe
  • Take a FREE Trial
  • About Us
  • Contact us
  • RSS

24 May 2013


The Pharma Letter
  • Home
  • 7 Day Premium Trial
  • Pharmaceuticals
  • Biotechnology
  • Generics
  • Events
  • Companies
  • Drugs
  • Subscribe

Companies

Top Ten Companies // Browse A - Z of companies

  • Merck KGaA (Merck)
  • Merck (Merck KGaA)
  • Pfizer
  • Roche
  • Novartis
  • GlaxoSmithKline (GSK)
  • GSK (GlaxoSmithKline)
  • Bristol-Myers Squibb
  • Lilly
  • Bayer

Browse the A - Z of Companies

  • #
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

H

  • H. Lundbeck
  • H3 Biomedicine
  • Hadasit Bio-Holdings
  • Haemonetics
  • Hainan Haiyao
  • Halo Pharmaceutical
  • Halo Therapeutics
  • Halozyme Therapeutics
  • Hamilton
  • Handa Pharmaceuticals
  • Handok Pharmaceuticals
  • Hanmi Pharmaceutical
  • Hanwha Chemical
  • Harbin Gloria Pharma
  • Hawthorn Pharmaceuticals
  • Health Protection Agency
  • Healthtronics
  • Hebei
  • Hebei Aoxing
  • Helix BioPharma
  • HELM AG
  • Helsinn
  • Hemerus Medical
  • Hemispherx BioPharma
  • Hemobras
  • Hemofarm
  • Heparinex
  • Heptares Therapeutics
  • Herborium
  • Hetero Group
  • Hi-Tech Pharmacal
  • Hikkma
  • Hikma Pharmaceuticals
  • Hisamitsu Pharma
  • Histogenics
  • Hisun-Pfizer
  • Hologic
  • Horizon Discovery
  • Horizon Pharma
  • Hospira
  • Hovid Sdn Bhd
  • Hovione
  • HRA Pharma
  • Hubei Haosun
  • Hudson Biopharma
  • Human Genome Sciences
  • Human Stem Cell Institute
  • Hunan Dongting
  • Hutchison MediPharma
  • Hutchison MediTech
  • HUYA Bioscience
  • HUYA Biscience
  • Hybrigenics
  • Hyperion Therapeutics
  • Hypermarcas
  • Hyupjin Corp
  • Hot Topics
  • Most Read
  • Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
  • Is the diabetes market facing a blockbuster-free future?
  • Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
  • Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
  • Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
  • Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
  • Is the diabetes market facing a blockbuster-free future?
  • Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
  • Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
  • Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth

30 Day Premium Trial


Events

Twitter Right banner

RSS



© 2013 thepharmaletter.com

  • Home
  • RSS
  • About Us
  • Subscribe
  • Terms and Conditions
  • Article Archive
Site powered by WORKSsitebuilder CMS